These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 17590116)

  • 1. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)].
    Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M;
    Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
    Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
    Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G; Eberhardt K; Geborek P
    Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
    Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of rheumatoid arthritis (RA) biotherapies in France.
    Maravic M
    Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
    Harrison DJ; Huang X; Globe D
    Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.